Adam Feuerstien tips off that a response from a FDA spokesperson on MAP Pharmaceuticals' (MAPP...

|About: MAP Pharmaceuticals, Inc. (MAPP)|By:, SA News Editor

Adam Feuerstien tips off that a response from a FDA spokesperson on MAP Pharmaceuticals' (MAPP +6.9%) Levadex "sounds like a rejection" for the drug that aims to treat migraine headaches. Shares of MAPP are up 30% YTD, helped in part by speculation that an approval on the drug could help the company ring up sales of over $100M in 2013.